Instil Bio Inc
TIL11.270USD
+0.175+1.58%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
76.43MMarket Cap
LossP/E TTM
More Details of Instil Bio Inc Company
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
Instil Bio Inc Info
Ticker SymbolTIL
Company nameInstil Bio Inc
IPO dateMar 19, 2021
CEOCrouch (Bronson)
Number of employees14
Security typeOrdinary Share
Fiscal year-endMar 19
Address3963 Maple Avenue
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75219
Phone19724993350
Websitehttps://instilbio.com/
Ticker SymbolTIL
IPO dateMar 19, 2021
CEOCrouch (Bronson)
Company Executives of Instil Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Dr. Neil W. Gibson, Ph.D.
Dr. Neil W. Gibson, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
160.00K
--
Mr. Bronson Crouch
Mr. Bronson Crouch
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
116.89K
-77.46%
Dr. George Matcham, Ph.D.
Dr. George Matcham, Ph.D.
Independent Director
Independent Director
30.00K
-21.26%
Dr. Neil W. Gibson, Ph.D.
Dr. Neil W. Gibson, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Kent Mcgaughy, Jr.
Mr. R. Kent Mcgaughy, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Curative Ventures Management LLC
28.00%
BML Capital Management LLC
9.52%
CPMG, Inc.
6.06%
Vivo Capital, LLC
4.32%
Invus Public Equities Advisors, LLC
3.01%
Other
49.10%
Shareholders
Shareholders
Proportion
Curative Ventures Management LLC
28.00%
BML Capital Management LLC
9.52%
CPMG, Inc.
6.06%
Vivo Capital, LLC
4.32%
Invus Public Equities Advisors, LLC
3.01%
Other
49.10%
Shareholder Types
Shareholders
Proportion
Venture Capital
32.32%
Investment Advisor
17.94%
Hedge Fund
10.12%
Investment Advisor/Hedge Fund
5.36%
Individual Investor
4.53%
Research Firm
1.82%
Corporation
1.77%
Other
26.15%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
131
4.62M
68.51%
-2.51M
2025Q2
139
5.74M
87.50%
-1.80M
2025Q1
177
6.10M
93.36%
-1.38M
2024Q4
187
6.08M
93.21%
-646.76K
2024Q3
221
6.16M
94.70%
+69.47K
2024Q2
217
4.68M
71.90%
-1.71M
2024Q1
222
4.70M
72.22%
-1.19M
2023Q4
226
4.39M
67.44%
-1.16M
2023Q3
227
4.47M
68.70%
-1.13M
2023Q2
230
4.57M
70.22%
-1.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Curative Ventures Management LLC
1.90M
28.13%
+1.00
+0.00%
Jun 30, 2025
BML Capital Management LLC
534.90K
7.92%
+118.18K
+28.36%
Jun 30, 2025
CPMG, Inc.
410.92K
6.09%
-1.00
-0.00%
Jun 30, 2025
Vivo Capital, LLC
292.74K
4.34%
-292.74K
-50.00%
Jun 30, 2025
Invus Public Equities Advisors, LLC
203.93K
3.02%
--
--
Jun 30, 2025
Millennium Management LLC
108.10K
1.6%
-104.15K
-49.07%
Jun 30, 2025
The Vanguard Group, Inc.
168.10K
2.49%
--
--
Jun 30, 2025
Sectoral Asset Management Inc.
86.22K
1.28%
+53.37K
+162.47%
Jun 30, 2025
Laumas (Sandeep)
160.00K
2.37%
--
--
Sep 10, 2025
SB2A Management LLC
120.00K
1.78%
--
--
Apr 02, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares US Small-Cap Equity Factor ETF
0.01%
Texas Capital Texas Small Cap Equity Index ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Tema Oncology ETF
0%
iShares US Small-Cap Equity Factor ETF
Proportion0.01%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
DFA Dimensional US Core Equity Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
Date
Type
Ratio
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
Dec 05, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Instil Bio Inc?
The top five shareholders of Instil Bio Inc are:
Curative Ventures Management LLC holds 1.90M shares, accounting for 28.13% of the total shares.
BML Capital Management LLC holds 534.90K shares, accounting for 7.92% of the total shares.
CPMG, Inc. holds 410.92K shares, accounting for 6.09% of the total shares.
Vivo Capital, LLC holds 292.74K shares, accounting for 4.34% of the total shares.
Invus Public Equities Advisors, LLC holds 203.93K shares, accounting for 3.02% of the total shares.
Curative Ventures Management LLC holds 1.90M shares, accounting for 28.13% of the total shares.
BML Capital Management LLC holds 534.90K shares, accounting for 7.92% of the total shares.
CPMG, Inc. holds 410.92K shares, accounting for 6.09% of the total shares.
Vivo Capital, LLC holds 292.74K shares, accounting for 4.34% of the total shares.
Invus Public Equities Advisors, LLC holds 203.93K shares, accounting for 3.02% of the total shares.
What are the top three shareholder types of Instil Bio Inc?
The top three shareholder types of Instil Bio Inc are:
Curative Ventures Management LLC
BML Capital Management LLC
CPMG, Inc.
Curative Ventures Management LLC
BML Capital Management LLC
CPMG, Inc.
How many institutions hold shares of Instil Bio Inc (TIL)?
As of 2025Q3, 131 institutions hold shares of Instil Bio Inc, with a combined market value of approximately 4.62M, accounting for 68.51% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.99%.
What is the biggest source of revenue for Instil Bio Inc?
In --, the -- business generated the highest revenue for Instil Bio Inc, amounting to -- and accounting for --% of total revenue.
